King Luther Capital Management Corp Makes New $2.24 Million Investment in TransMedics Group, Inc. $TMDX
King Luther Capital Management Corp has made a new investment of $2.24 million in TransMedics Group, Inc. (NASDAQ:TMDX), acquiring 20,000 shares. This comes amidst significant institutional interest, with total institutional ownership reaching 99.67%, and an average analyst rating of "Moderate Buy" with a target price of $144.25. Despite positive analyst sentiment and institutional growth, insiders have sold shares totaling $1.26 million in the last three months.
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
TransMedics Group, Inc. announced inducement grants of non-qualified stock options and restricted stock units to 14 new employees, including Chief Commercial Officer Giovanni Cecere. These grants, totaling 40,089 shares and 26,549 units respectively, were made in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to vesting schedules. The inducement plan aims to attract and retain talent for the medical technology company focused on organ transplant therapy.
New TransMedics hires get stock awards at $135.50 a share
TransMedics (TMDX) announced equity grants to 14 new employees on February 18, 2026, including stock options for 40,089 shares and 26,549 restricted stock units. The options have an exercise price of $135.50 and the awards, including a significant portion to the Chief Commercial Officer, were approved under Nasdaq Listing Rule 5635(c)(4). These grants are part of the company's broader growth strategy following FDA approvals and headquarters expansion.
Bronstein, Gewirtz & Grossman, LLC Is Investigating TransMedics Group, Inc. (TMDX) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against TransMedics Group, Inc. (TMDX) regarding alleged corporate wrongdoing. The investigation encourages investors who purchased TransMedics securities before February 3, 2022, and still hold them, to connect with the firm to assist in the investigation. The firm operates on a contingency fee basis and aims to recover investor capital and ensure corporate accountability.
FDA Greenlights TransMedics ENHANCE Heart Trial Shaping Growth Prospects
TransMedics Group (NasdaqGM:TMDX) has received full FDA approval for its Next-Generation OCS ENHANCE Heart trial, a significant regulatory milestone for its heart transplant organ care system. This approval specifically applies to the company's next-generation Organ Care System platform for heart transplants, which aims to improve organ preservation and assessment outside the human body. The trial framework, focusing on prolonged heart perfusion and comparing it to static cold storage, provides a clearer path for clinical data that could influence the adoption of the OCS platform by transplant centers and payors.
How to watch TransMedics' March investor events online
TransMedics (Nasdaq: TMDX) will present at two investor conferences in March 2026: the TD Cowen 46th Annual Health Care Conference on March 2nd and the Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 16th. Webcasts for both events will be available on the Investors section of the TransMedics website. This announcement follows recent regulatory milestones and expansion plans, which have previously resulted in mixed share-price reactions for the company.
TransMedics to Present at Upcoming March Investor Conferences
TransMedics Group, Inc. will participate in two investor conferences in March 2026. The medical technology company, which specializes in organ transplant therapy, will have a fireside chat at the TD Cowen 46th Annual Health Care Conference and virtually at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference. Webcasts of the presentations will be available on the company's investor relations website.
TransMedics Group (TMDX) to Release Quarterly Earnings on Tuesday
TransMedics Group (TMDX) is scheduled to announce its Q4 2025 earnings on Tuesday, February 24th, with analysts forecasting earnings per share of $0.41 and revenue of $155.279 million. Despite recent insider selling, which saw executives offload over $1.26 million in shares, analyst sentiment is largely positive, reflected in a "Moderate Buy" consensus and an average price target above the current share price. The company specializes in organ preservation and transport systems, aiming to improve transplant outcomes and expand the donor organ pool.
TransMedics Group, Inc. (TMDX) Stock Analysis: Unlocking a 11% Upside in the Medical Device Sector
TransMedics Group, Inc. (TMDX) is a strong player in the medical device sector with a $4.44 billion market cap and innovative Organ Care System. Analysts are predominantly positive on TMDX, with an average target price suggesting an 11.06% upside, driven by impressive revenue growth and strategic reinvestment of earnings. Despite neutral short-term technical indicators, the company's focus on expansion and innovation in organ transplant therapy presents a promising opportunity for growth-oriented investors.
TransMedics Group Inc (NASDAQ:TMDX) Screened as a High-Momentum Growth Stock
TransMedics Group Inc (NASDAQ:TMDX) has been identified as a high-momentum growth stock based on Louis Navellier’s "The Little Book That Makes You Rich" strategy. The company demonstrates strong financial performance, including positive earnings revisions and surprises, accelerating revenue and EPS growth, widening profit margins, strong cash flow, and high return on equity. While traditional valuation metrics appear costly, its impressive growth rate makes its valuation more acceptable relative to peers.
Bastion Asset Management Inc. Purchases New Stake in TransMedics Group, Inc. $TMDX
Bastion Asset Management Inc. has acquired a new stake of 44,887 shares in TransMedics Group, Inc. (NASDAQ:TMDX), valued at approximately $5.13 million, making it the 11th largest holding in Bastion's portfolio. Other institutional investors like Marshall Wace LLP and Zevenbergen Capital Investments LLC have also significantly increased their positions in TransMedics Group. The company has a consensus "Moderate Buy" rating from analysts with an average price target of $144.25, while insider selling has also been reported recently.
Public Sector Pension Investment Board Raises Position in TransMedics Group, Inc. $TMDX
The Public Sector Pension Investment Board increased its stake in TransMedics Group (NASDAQ:TMDX) by 15.3% in Q3, now owning 132,972 shares valued at $14.92 million. This comes despite recent insider selling by Director David Weill and CFO Gerardo Hernandez, and a generally positive "Moderate Buy" consensus from analysts with an average price target of $144.25. The company specializes in advanced organ preservation and transport systems, with 99.67% of its stock held by institutional investors.
How Investors May Respond To TransMedics Group (TMDX) Full IDE Approval For ENHANCE Heart Trial
TransMedics Group (TMDX) recently received full FDA approval for its IDE for the ENHANCE Heart trial, a two-part study for prolonged heart perfusion in organ transplantation. This approval is seen as a positive step for the company's organ care platform, reinforcing its investment narrative and growth expectations. However, investors also need to consider potential risks such as clinical results falling short, regulatory scrutiny, or reimbursement challenges.
Wall Street Zen Upgrades TransMedics Group (NASDAQ:TMDX) to Buy
Wall Street Zen has upgraded TransMedics Group (NASDAQ:TMDX) to a "Buy" rating, contributing to an overall "Moderate Buy" consensus from analysts with an average price target of $144.25. The company's stock trades around $129.84 with a market cap of $4.44 billion and a P/E ratio of approximately 52.6. Recent insider selling of 8,920 shares worth about $1.26 million has been noted, while institutional ownership stands at nearly 99.67%.
Bronstein, Gewirtz & Grossman, LLC Encourages TransMedics Group, Inc. (TMDX) Investors to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. (TMDX) who bought securities before February 3, 2022, and still hold them. The investigation focuses on whether the company's officers or directors engaged in corporate wrongdoing. Investors are encouraged to visit the firm's website or contact them for more information and to assist with the investigation.
How Do Investors Really Feel About TransMedics Group Inc?
TransMedics Group Inc. (NYSE: TMDX) has seen an 8.37% increase in short interest, with 7.89 million shares sold short, representing 39.6% of its float. This rise indicates a growing bearish sentiment among investors towards the company. Compared to its peers, TransMedics Group Inc. also has a higher short interest percentage, suggesting more negative sentiment than its industry average.
TransMedics to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
TransMedics Group, Inc. will release its financial results for the fourth quarter and full year 2025 after market close on Tuesday, February 24, 2026. The company's management team will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results. Investors can access the call via phone or a webcast on the TransMedics website.
TransMedics to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
TransMedics Group, Inc. (Nasdaq: TMDX) announced it will release its fourth-quarter and full-year 2025 financial results on February 24, 2026, after market close. A conference call hosted by management will follow at 4:30 p.m. ET to discuss the results. Investors can access the call via phone or a webcast on the company's website.
TransMedics to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
TransMedics Group, Inc. (Nasdaq: TMDX) announced it will release its financial results for the fourth quarter and full year 2025 after market close on Tuesday, February 24, 2026. The company's management will host a conference call at 4:30 p.m. ET/1:30 p.m. PT to discuss the results, with details provided for investors to listen via phone or webcast.
TransMedics Receives Full and Unconditional FDA IDE Approval for Next-Generation OCS Heart ENHANCE Trial
TransMedics Group, Inc. has received full FDA IDE approval for its Next-Generation OCS Heart ENHANCE trial. This trial, expected to be the largest heart preservation for transplant trial globally with over 650 patients, aims to demonstrate the superiority of OCS Heart perfusion over static cold storage and support expanded clinical indications. This approval follows earlier conditional approval and a full IDE approval for the OCS DENOVO Lung trial, positioning these trials as significant catalysts for adoption in heart and lung transplantation.
TransMedics Receives Full and Unconditional FDA IDE Approval for Next-Generation OCS Heart ENHANCE Trial
TransMedics Group, Inc. announced full FDA IDE approval for its Next-Generation OCS ENHANCE Heart trial, following previous approvals for its lung trial and conditional heart trial. The ENHANCE trial, expected to include over 650 patients, aims to demonstrate the prolonged heart perfusion capability and superiority of the OCS Heart System compared to static cold storage methods for donation-after-brain-death cases. This approval is a significant step towards expanding clinical indications and solidifying the OCS Heart platform's effectiveness in enhancing and improving cardiac function.
New York State Common Retirement Fund Sells 134,406 Shares of TransMedics Group, Inc. $TMDX
The New York State Common Retirement Fund significantly reduced its stake in TransMedics Group (NASDAQ: TMDX) by selling 134,406 shares, leaving it with 15,240 shares worth $1.71 million. Despite this large sale, other institutional investors increased their positions, maintaining a high overall institutional ownership of 99.67%. Insiders have also been selling shares, while analysts have a consensus "Moderate Buy" rating for the stock with a target price of $144.25.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against TransMedics Group, Inc. (TMDX) And Encourages Stockholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into potential corporate wrongdoing by TransMedics Group, Inc. (TMDX). The firm is urging investors who purchased TransMedics securities before February 3, 2022, and still hold them, to come forward and assist with the investigation. The investigation aims to determine if the company's officers and/or directors engaged in misconduct.
Principal Financial Group Inc. Purchases 53,995 Shares of TransMedics Group, Inc. $TMDX
Principal Financial Group Inc. significantly increased its stake in TransMedics Group, Inc. by 28.7% in the third quarter, acquiring 53,995 additional shares. This brings their total holdings to 242,039 shares, valued at approximately $27.16 million, representing 0.71% ownership of the company. Despite insider selling activity by Anil P. Ranganath and David Weill, analysts maintain a "Moderate Buy" consensus rating for TransMedics Group, with a mean price target of $144.25.
Renaissance Group LLC Acquires Shares of 76,078 TransMedics Group, Inc. $TMDX
Renaissance Group LLC recently acquired a new stake in TransMedics Group (NASDAQ:TMDX), purchasing 76,078 shares valued at approximately $8.54 million. This acquisition makes Renaissance Group LLC the owner of 0.22% of TransMedics Group. Despite institutional purchases, company insiders have been net sellers, offloading 8,920 shares worth about $1.26 million in the last 90 days.
TD Cowen Sticks to Its Buy Rating for TransMedics Group (TMDX)
TD Cowen analyst Josh Jennings reiterated a Buy rating on TransMedics Group (TMDX) with a price target of $170.00. The company reported significant revenue and profit growth in its latest quarter, though corporate insider sentiment shows an increase in share sales. This reaffirmation comes as other analysts also weigh in on TMDX's stock performance and future prospects.
Bronstein, Gewirtz & Grossman, LLC Is Investigating TransMedics Group, Inc. (TMDX) And Encourages Stockholders to Connect
Bronstein, Gewirtz & Grossman, LLC has announced an investigation into potential corporate wrongdoing by TransMedics Group, Inc. (TMDX). The firm is encouraging investors who purchased TransMedics securities before February 3, 2022, and still hold them, to contact them to assist with the investigation. The investigation focuses on whether the company's officers or directors engaged in misconduct, with the law firm offering its services on a contingency fee basis.
TransMedics Group Inc (NASDAQ:TMDX): A GARP Stock with Strong Growth at a Fair Price
TransMedics Group Inc (NASDAQ:TMDX) has been identified as a Growth At a Reasonable Price (GARP) stock, demonstrating strong growth potential at a fair valuation. The company boasts remarkable past and projected revenue and EPS growth, supported by satisfactory profitability and strong financial health, including excellent liquidity. Despite a seemingly high P/E ratio, its valuation appears reasonable when compared to industry peers and adjusted for growth, making it a notable pick for investors seeking balanced growth.
Up 95% In Last 12 Months, Can TransMedics Stock Keep Climbing In 2026?
TransMedics Group (TMDX) reported strong Q3 2025 revenue of $144 million and is expanding its transplant logistics network, including international plans for Italy in early 2026. The company's stock has risen 95% in the last 12 months, and a TIKR valuation model projects further growth to $181 by December 2027, implying a 35% total return. This projection is based on 24.5% annual revenue growth, 19.1% operating margins, and a 51.2x P/E multiple despite execution risks and market adoption cycles.
Reasons to retain TransMedics stock in your portfolio for now
This article analyzes reasons to retain TransMedics stock in a portfolio. It likely discusses factors such as the company's financial performance, market position, and future growth prospects that make it a compelling hold. The analysis would aim to justify the current investment in TDMC given existing market conditions and company-specific developments.
TransMedics Group, Inc. (TMDX): A Bull Case Theory
This article summarizes a bullish thesis on TransMedics Group, Inc. (TMDX), highlighting its differentiated Organ Care System technology which improves organ viability and expands the transplant market. The company has shifted to a recurring-revenue model, achieved profitability, and shows significant growth potential through increased U.S. penetration, entry into kidney transplants, and potential international expansion, despite some risks.
TransMedics Group Inc (NASDAQ:TMDX) Shows Strong Growth Momentum and Technical Setup
TransMedics Group Inc (NASDAQ:TMDX) is identified as a strong investment candidate due to its significant growth momentum and positive technical setup. The company exhibits outstanding earnings and sales growth, with a high ChartMill High Growth Momentum Rating, a top Technical Rating, and a good Setup Quality Rating. This indicates a strong uptrend supported by solid financial improvement, currently pausing before a potential further advance.
Lisanti Capital Growth LLC Grows Stock Holdings in TransMedics Group, Inc. $TMDX
Lisanti Capital Growth LLC significantly increased its stake in TransMedics Group, Inc. (NASDAQ:TMDX) by 62.0% in the third quarter, now owning 56,901 shares valued at approximately $6.38 million. This makes TMDX the 15th largest holding for the fund, representing about 1.6% of its portfolio. Various other institutional investors also modified their holdings, with institutional ownership of the company now standing at 99.67%, while company insiders sold shares worth $1.26 million over the last three months, leaving them with 7.00% ownership.
TransMedics Group Inc. (NASDAQ:TMDX) Combines Strong Growth with Bullish Technical Momentum
TransMedics Group Inc. (NASDAQ:TMDX) is highlighted as an investment opportunity combining strong fundamental growth with bullish technical momentum. The company shows high earnings and revenue growth, with positive future projections, and its stock exhibits a long-term upward trend and recent stabilization near highs, indicating potential for continued price increases. While valuation appears high by standard metrics, its PEG ratio suggests future growth might not be fully valued, making it an attractive prospect for growth investors.
TransMedics Group (NASDAQ:TMDX) Downgraded to "Hold" Rating by Wall Street Zen
Wall Street Zen has downgraded TransMedics Group (NASDAQ:TMDX) from a "buy" to a "hold" rating, though the overall analyst consensus remains a "Moderate Buy" with an average price target of $144.25. The medical device company, specializing in organ preservation, reported Q3 EPS of $0.66, beating estimates, and revenue growth of 32.2% year-over-year. Institutional investors hold a significant portion of the stock, while insiders have recently sold shares.
Assessing TransMedics Group (TMDX) Valuation After Nasdaq 100 Inclusion
TransMedics Group (TMDX) has recently been added to the Nasdaq 100, following a strong performance with a 115.15% one-year total shareholder return. While a detailed narrative suggests the stock is 2.6% undervalued at $140.99, relying on future growth and margin expansion, its current P/E ratio of 52.5x is significantly higher than peers, indicating potential valuation risk if growth expectations aren't met. The article encourages investors to consider these contrasting valuation perspectives and build their own assumptions.
Y Intercept Hong Kong Ltd Sells 11,812 Shares of TransMedics Group, Inc. $TMDX
Y Intercept Hong Kong Ltd reduced its stake in TransMedics Group, Inc. (NASDAQ:TMDX) by 32.6% during the third quarter, selling 11,812 shares and retaining 24,380 shares valued at approximately $2.74 million. This sale is part of broader insider selling, while institutional investors show mixed activity. Despite a slight revenue miss, TransMedics exceeded EPS expectations, analysts maintain a "Moderate Buy" rating, and the stock exhibits a relatively high beta.
TransMedics Group, Inc. (NASDAQ:TMDX) Given Average Recommendation of "Moderate Buy" by Analysts
TransMedics Group, Inc. (NASDAQ:TMDX) has received an average "Moderate Buy" rating from analysts, with a 1-year price objective of $144.25. The company recently reported Q3 earnings of $0.66 per share, beating consensus estimates, and revenue of $143.82 million. Insider selling has been noted from the CFO and a Director, while institutional investors have adjusted their holdings.
Universal Beteiligungs und Servicegesellschaft mbH Sells 396,232 Shares of TransMedics Group, Inc. $TMDX
Universal Beteiligungs und Servicegesellschaft mbH significantly reduced its stake in TransMedics Group, Inc. by selling 396,232 shares, retaining approximately 0.19% of the company. Despite this institutional selling, TransMedics reported a strong quarterly EPS beat and revenue growth, though it slightly missed analyst revenue estimates. The stock currently holds a "Moderate Buy" consensus rating from analysts, with insider selling also noted in the past 90 days.
Even Though TransMedics Group (NASDAQ:TMDX) Has Lost US$276m Market Cap in Last 7 Days, Shareholders Are Still up 519% Over 5 Years
TransMedics Group (NASDAQ:TMDX) shareholders have seen an impressive 519% return over the last five years, despite a recent US$276 million market cap loss. The company's transition from loss to profitability is highlighted as a key driver for its strong share price gains. Recent insider buying further suggests a positive outlook for the company's future performance.
Precision Trading with Transmedics Group Inc. (TMDX) Risk Zones
This article analyzes Transmedics Group Inc. (TMDX) with AI-generated trading strategies. It highlights a weak near-term sentiment but strong mid and long-term outlooks, providing specific entry, target, and stop-loss zones for position, momentum, and risk-hedging strategies. The analysis emphasizes a significant risk-reward short setup and offers multi-timeframe signal analysis for precise trading.
Is TransMedics’ Incentive‑Backed Somerville Campus Reshaping The Investment Case For TransMedics Group (TMDX)?
TransMedics Group (TMDX) is establishing a new global headquarters in Somerville, Massachusetts, an initiative supported by significant incentives from the Massachusetts Life Sciences Center and Somerville. The move, expected by January 2028, aims to integrate corporate, R&D, and manufacturing functions and is linked to job creation and local tax revenue. While the expansion reinforces management's long-term vision, its benefits are anticipated to be gradual, with investors urged to consider potential execution and cost risks given the stock's current valuation.
Emerald Mutual Fund Advisers Trust Sells 17,205 Shares of TransMedics Group, Inc. $TMDX
Emerald Mutual Fund Advisers Trust reduced its stake in TransMedics Group by 6.7%, selling 17,205 shares, while other institutional investors significantly increased their positions, leading to institutional ownership of 99.67%. Insiders have been net sellers, with 13,062 shares worth approximately $1.8 million sold in the last 90 days. Analysts maintain a "Moderate Buy" rating with a consensus target price of $144.25, following a quarter where TransMedics beat EPS estimates and achieved 32.2% year-over-year revenue growth.
Is TransMedics’ Incentive‑Backed Somerville Campus Reshaping The Investment Case For TransMedics Group (TMDX)?
TransMedics Group, Inc. is establishing a new global headquarters in Somerville, Massachusetts, with the move backed by significant tax incentives from the state and local government. This expansion aims to integrate corporate, R&D, and manufacturing functions, reinforcing the company's growth narrative. While the incentives may mitigate some immediate costs, the benefits to the investment case are expected to be gradual, with current share prices already reflecting high expectations.
BioMed Realty and TransMedics complete 498,000 s/f lease at Assembly Innovation Park
BioMed Realty and medical technology company TransMedics Group Inc. have finalized a 498,000 square foot lease at Assembly Innovation Park in Somerville, MA. This 12-story, LEED Platinum and WELL certified facility will become TransMedics' new global headquarters and manufacturing hub for 16 years, with an option for future growth through an acquired adjacent land parcel. The development is strategically located in Assembly Sq. with excellent access to academic institutions, clinical centers, and life sciences talent.
Emerald Advisers LLC Has $43.49 Million Holdings in TransMedics Group, Inc. $TMDX
Emerald Advisers LLC reduced its stake in TransMedics Group, Inc. by 11.8% in the third quarter, ending with 387,588 shares valued at $43.49 million. Despite this, TransMedics reported strong earnings, exceeding analyst expectations with an EPS of $0.66 against a $0.37 consensus and a 32.2% increase in revenue. Analysts maintain a "Moderate Buy" rating for TMDX, with an average price target of $144.25.
TransMedics stock falls after Bridge to Life wins FDA clearance for liver device By Investing.com
TransMedics Group Inc. (NASDAQ:TMDX) stock fell over 5% after Bridge to Life received FDA clearance for its VitaSmart device for liver transplantation. While VitaSmart presents a competitive challenge, analysts like TD Cowen's Joshua Jennings believe its impact on TransMedics' OCS Liver system will be limited due to differing technologies. TD Cowen maintained a Buy rating on TransMedics, citing confidence in the company's continued market dominance.
TransMedics stock falls after Bridge to Life wins FDA clearance for liver device By Investing.com
TransMedics Group Inc. stock fell after Bridge to Life received FDA clearance for its VitaSmart liver transplantation device. While VitaSmart presents a new competitor, analysts suggest its impact on TransMedics may be limited due to fundamental differences in technology and the inability of VitaSmart to provide key organ function assessment biomarkers. Despite the competition, TD Cowen maintains a Buy rating on TransMedics, expecting it to retain market dominance.
TransMedics (TMDX) Shares Decline Amid FDA Clearance for Rival S
TransMedics (TMDX) shares declined by 5% following FDA clearance of Bridge to Life's VitaSmart Hypothermic Oxygenated Perfusion System, a rival liver perfusion device. Despite this competitive pressure, TransMedics, known for its Organ Care System (OCS), demonstrates strong financial health with robust revenue growth and profitability. The company operates in the innovative medical devices sector, evidenced by its $4.61 billion market capitalization and positive analyst outlook, though its stock exhibits high volatility.
TransMedics Group (NASDAQ:TMDX) Shares Down 4.3% - Should You Sell?
TransMedics Group (NASDAQ:TMDX) shares fell 4.3% during mid-day trading with lower-than-average volume. Despite beating EPS expectations and having positive analyst sentiment with a "Moderate Buy" consensus, insider selling of roughly $1.8 million has occurred in the last 90 days. The company, which specializes in organ preservation systems, maintains a market cap of $4.61 billion.
